Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Darragh Storan"'
Autor:
Darragh Storan, Joseph Lavelle, Anne-Marie Burke, Mary Hamzawi, Orna Brett-Kilmurray, Noemi De Dominicis, Louise McHugh, Hugh E Mulcahy
Publikováno v:
Frontline Gastroenterology. 14:132-137
ObjectivePatients with inflammatory bowel disease (IBD) traditionally receive follow-up care at face-to-face outpatient clinics. During the COVID-19 pandemic, gastroenterology societies recommended IBD clinics to be carried out remotely where possibl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a57e8f9c055a5c78539d6203d065ba0
https://doi.org/10.1136/flgastro-2022-102198
https://doi.org/10.1136/flgastro-2022-102198
Autor:
Joseph Lavelle, Darragh Storan, Varsha Eswara Murthy, Noemi De Dominicis, Hugh E. Mulcahy, Louise McHugh
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 10; Pages: 2757
Psychological intervention targeting distress is now considered an integral component of inflammatory bowel disease (IBD) management. However, significant barriers to access exist which necessitate the development of effective, economic, and accessib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e53adf944f7d8ce64db64fba3c0585c
https://pubmed.ncbi.nlm.nih.gov/35628884
https://pubmed.ncbi.nlm.nih.gov/35628884
Publikováno v:
Gastrointestinal Endoscopy. 94:875-876
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83d4d435750130c74407285c16580cf4
https://doi.org/10.1016/j.gie.2021.05.013
https://doi.org/10.1016/j.gie.2021.05.013
Publikováno v:
Clin Gastroenterol Hepatol
BACKGROUND & AIMS: A subset of patients with Crohn’s disease (CD) do not respond to ustekinumab at the standard dose of 90 mg every 8 weeks. Little is known about the efficacy of shortening the interval between doses. METHODS: We performed a retros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7456f108dcf32dcb78a66435504b5577
https://pubmed.ncbi.nlm.nih.gov/32109634
https://pubmed.ncbi.nlm.nih.gov/32109634
Autor:
Fabiana Castiglione, Waqqas Afif, Claire Liefferinckx, Shaji Sebastian, Davide De Marco, Viktor Domislovic, Marie Truyens, Marieke Pierik, Charlie W. Lees, Cyrielle Gilletta, Tamás Molnár, Nicola Imperatore, Eran Zittan, Zeljko Krznaric, Darragh Storan, A Cremer, Nikolas Plevris, Sally Myers, David Drobne, Stephan R. Vavricka, Glen A. Doherty, Denis Franchimont, Iria Baston‐Rey, Shomron Ben-Horin, Roni Weisshof, Triana Lobatón, Zuzana Zelinkova, R Harris, Jurij Hanzel, Klaudia Farkas, Bar‐Gil Shitrit Ariella, Vince B. C. Biemans, Yago González Lama, Uri Kopylov, Frank Hoentjen, Manuel Barreiro-de Acosta
Publikováno v:
Alimentary Pharmacology & Therapeutics, 52(1), 135-142. Wiley
Alimentary pharmacology & therapeutics, 52 (1
Alimentary Pharmacology & Therapeutics, 52, 135-142
Alimentary Pharmacology & Therapeutics, 52, 1, pp. 135-142
Alimentary pharmacology & therapeutics, 52 (1
Alimentary Pharmacology & Therapeutics, 52, 135-142
Alimentary Pharmacology & Therapeutics, 52, 1, pp. 135-142
Ustekinumab is effective in Crohn's disease. However, a substantial proportion of patients will not respond or lose response to ustekinumab. The current evidence to support the effectiveness of dose-optimisation for ustekinumab nonresponse is limited
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d7add583785542b9fc194836d7b4ed2
https://cris.maastrichtuniversity.nl/en/publications/96db5010-8872-4688-89ef-cc762d22ce0f
https://cris.maastrichtuniversity.nl/en/publications/96db5010-8872-4688-89ef-cc762d22ce0f
Autor:
Nikolas Plevris, R Harris, V Domislović, Zeljko Krznaric, S. Shaji, Y. Gonzalez Lama, R. Weishof, David Drobne, Glen A. Doherty, Frank Hoentjen, Stephan R. Vavricka, Darragh Storan, Zuzana Zelinkova, M. Barrero de Acosta, Claire Liefferinckx, A Bar-Gil Shitrit, Triana Lobaton Ortega, Marie J. Pierik, Uri Kopylov, Sally Myers, Denis Franchimont, D. De Marco, Marie Truyens, A Cremer, Charlie W. Lees, Eran Zittan, Vince B. C. Biemans, Cyrielle Gilletta, Fabiana Castiglione, Nicola Imperatore, Jurij Hanzel, Waqqas Afif, I. Baston-Rey, Shomron Ben-Horin
Publikováno v:
Journal of Crohn's and Colitis. 14:S111-S112
Background Ustekinumab (UST) is an effective agent for induction and maintenance of response and remission in Crohn’s disease (CD). In addition to randomised controlled trials, an abundance of real-world evidence is available as well, suggesting th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f4cf3c70becefb28e5adad88c7c23bf
https://doi.org/10.1093/ecco-jcc/jjz203.113
https://doi.org/10.1093/ecco-jcc/jjz203.113
Publikováno v:
ESGE Days 2019.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad7483e9ec221ba593b9e59dab0bd3da
https://doi.org/10.1055/s-0039-1681683
https://doi.org/10.1055/s-0039-1681683
Publikováno v:
ACG Case Reports Journal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1426af0c329715f2b746a09b139335a0
https://doi.org/10.14309/crj.0000000000000331
https://doi.org/10.14309/crj.0000000000000331